4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
is enrolling at a rapid pace indicating considerable interest from investigators and patients. In addition, we are also on track to be the first to use CRISPR
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
unmet need with itepekimab our investigational IL-33 antibody designed to help COPD patients who are former smokers. With significant runway for growth
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
, and that we are acquiring full development and commercialization rights for 2seventy bio's pipeline of investigational immune cell therapies. We have
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
results further strengthen the clinical profile of aflibercept 8-milligram and position this investigational medicine to become the future standard of care
- Prev
- 1
- Next